Want to see HK:2367 full AI Analyst Report?
Top Page
Giant Biogene Holding Co. Ltd.
(2367)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$30.00
▲(4.31% Upside)
Action:Reiterated
Date:08/30/26
The score is driven primarily by strong underlying financial quality (high profitability and very low leverage) and a reasonable valuation (P/E ~14.7 with a ~2.3% dividend yield). These positives are partially offset by weak technicals, with the stock trading below key moving averages and bearish momentum indicators (negative MACD, RSI ~40).
Positive Factors
Extremely low leverage
Minimal debt reduces financial risk, interest burdens, and refinancing dependence. This gives Giant Biogene substantial flexibility to fund operations, protect margins during weaker demand, and invest in growth without materially increasing balance-sheet strain.
Negative Factors
Revenue contraction
A full-year revenue decline signals weaker demand or reduced momentum rather than a merely temporary reporting fluctuation. Sustained contraction could limit operating leverage, weaken market expansion, and make it harder to maintain the company’s previous growth trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Extremely low leverage
Minimal debt reduces financial risk, interest burdens, and refinancing dependence. This gives Giant Biogene substantial flexibility to fund operations, protect margins during weaker demand, and invest in growth without materially increasing balance-sheet strain.
Read all positive factors
Giant Biogene Holding Co. Ltd. (2367) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$28.14B
Dividend Yield2.31%
Average Volume (3M)4.23M
Price to Earnings (P/E)14.3
Beta (1Y)1.27
Revenue Growth-9.65%
EPS Growth-25.51%
CountryHK
Employees2,319
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)1.56
Shares Outstanding1,061,704,000
10 Day Avg. Volume2,890,835
30 Day Avg. Volume4,234,731
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.19
Price to Sales (P/S)5.73
P/FCF Ratio21.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$38.73Price Target Upside34.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.81
Revenue Forecast (FY)HK$6.06B
Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model
Company Description
Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. ...
Giant Biogene Holding Co. Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.28B | 5.52B | 5.54B | 3.52B | 2.36B | 1.55B |
| Gross Profit | 4.18B | 4.43B | 4.55B | 2.95B | 2.00B | 1.35B |
| EBITDA | 1.76B | 2.19B | 2.31B | 1.78B | 1.21B | 933.64M |
| Net Income | 1.66B | 1.91B | 2.06B | 1.45B | 1.00B | 828.13M |
Balance Sheet | ||||||
| Total Assets | 10.24B | 10.85B | 8.04B | 4.97B | 3.14B | 7.88B |
| Cash, Cash Equivalents and Short-Term Investments | 7.39B | 8.29B | 5.86B | 3.78B | 2.20B | 7.26B |
| Total Debt | 12.25M | 9.69M | 6.71M | 2.73M | 2.59M | 7.68B |
| Total Liabilities | 872.40M | 917.03M | 918.14M | 602.03M | 301.19M | 6.86B |
| Stockholders Equity | 9.36B | 9.92B | 7.11B | 4.36B | 2.83B | 1.02B |
Cash Flow | ||||||
| Free Cash Flow | 1.01B | 1.48B | 1.79B | 1.42B | 778.39M | 581.21M |
| Operating Cash Flow | 1.16B | 1.90B | 2.04B | 1.65B | 931.64M | 692.40M |
| Investing Cash Flow | -486.44M | -471.99M | -1.11B | -527.28M | -858.74M | 1.56B |
| Financing Cash Flow | -1.17B | 892.40M | 582.95M | 51.81M | -5.79B | 4.48B |
Giant Biogene Holding Co. Ltd. Technical Analysis
Negative
28.76
Price Trends
28.01
Negative
27.89
Negative
29.86
Negative
Market Momentum
-0.67
Positive
46.08
Neutral
43.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2367, the sentiment is Negative. The current price of 28.76 is above the 20-day moving average (MA) of 27.49, above the 50-day MA of 28.01, and below the 200-day MA of 29.86, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 46.08 is Neutral, neither overbought nor oversold. The STOCH value of 43.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2367.
Giant Biogene Holding Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$9.40B | 11.34 | 25.72% | 6.16% | 23.19% | -22.44% | |
71 Outperform | HK$28.14B | 14.28 | 17.22% | 2.31% | -9.65% | -25.51% | |
66 Neutral | HK$521.12M | 6.17 | 6.06% | 9.03% | 2.24% | -39.98% | |
65 Neutral | HK$25.05B | 8.66 | 10.98% | 7.50% | 2.19% | 10.78% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | HK$21.28B | -236.59 | -1.21% | 4.72% | -2.44% | 81.73% | |
46 Neutral | HK$910.96M | -15.85 | -12.81% | 0.53% | 13.43% | 7.72% |
* Consumer Defensive Sector Average
HK:2367
Giant Biogene Holding Co. Ltd.
26.04
-35.38
-57.61%
HK:1044
Hengan International Group Co
21.36
-2.04
-8.73%
HK:3828
Ming Fai International Holdings
0.72
-0.22
-23.65%
HK:0157
Natural Beauty Bio-Technology
0.46
-0.09
-15.74%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
22.80
-71.41
-75.80%
HK:6993
Blue Moon Group Holdings Ltd.
3.88
0.66
20.61%
Giant Biogene Holding Co. Ltd. Corporate Events
Giant Biogene’s Interim Profit Drops Amid Rising Expenses
Aug 18, 2026
Giant Biogene reported a decline in performance for the six months ended 30 June 2026, with revenue slipping 6.3% year on year to RMB 2.92 billion and gross profit down 8.8% to RMB 2.32 billion. Net profit fell 20.5% to RMB 939.5 million, while ba...
Giant Biogene Wins China Approval for First Recombinant Type III Collagen Neck Filler
Jun 17, 2026
Giant Biogene announced that its subsidiary Shaanxi Giant Biotechnology has received China’s medical device registration certificate for a cross-linked recombinant type III collagen implant designed for intradermal injection to correct moder...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.